Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.79 |
| ▸ | KDR | P35968 | 16/20 | 0.79 |
| ▸ | AURKA | O14965 | 8/20 | 0.66 |
| ▸ | TEK | Q02763 | 7/20 | 0.66 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.66 |
| ▸ | AURKB | Q96GD4 | 6/20 | 0.66 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.66 |
| ▸ | FLT4 | P35916 | 4/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3946358 | 0.95 | KDR (0.79) | EGFRKDRAURKATEKPDGFRB | |
| SCHEMBL2191250 | 0.95 | EGFR (0.79) | EGFRKDRAURKATEKPDGFRB | |
| SCHEMBL12507380 | 0.93 | EGFR (0.68) | EGFRKDRAURKATEKPDGFRB | |
| SCHEMBL2190824 | 0.93 | EGFR (0.78) | EGFRKDRAURKATEKPDGFRB | |
| SCHEMBL2190460 | 0.93 | EGFR (0.78) | EGFRKDRAURKATEKPDGFRB | |
| SCHEMBL12507084 | 0.88 | EGFR (0.68) | EGFRKDRAURKATEKPDGFRB | |
| SCHEMBL3947486 | 0.88 | EGFR (0.68) | EGFRKDRAURKATEKPDGFRB | |
| SCHEMBL3948578 | 0.88 | EGFR (0.78) | EGFRKDRAURKATEKPDGFRB | |
| SCHEMBL2192340 | 0.88 | EGFR (0.78) | EGFRKDRAURKATEKPDGFRB | |
| SCHEMBL2195995 | 0.88 | EGFR (0.78) | EGFRKDRAURKATEKPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172241-A1 | Benzazole analogues and uses thereof | 4SC AG (DE) | 2011-07-14 | — | — | US | disclosed |
| US-20110172241-A1 | Benzazole analogues and uses thereof | 4SC AG (DE) | 2011-07-14 | — | — | US | disclosed |
| US-20090270410-A1 | BENZAZOLE ANALOGUES AND USES THEREOF | 4SC AG (DE) | 2009-10-29 | — | — | US | disclosed |
| US-20090270410-A1 | BENZAZOLE ANALOGUES AND USES THEREOF | 4SC AG (DE) | 2009-10-29 | — | — | US | disclosed |
| US-20090270410-A1 | BENZAZOLE ANALOGUES AND USES THEREOF | 4SC AG (DE) | 2009-10-29 | — | — | US | disclosed |
| US-7576090-B2 | e.g. N-[2-(6,7-Dimethoxyquinazolin-4-ylamino)benzothiazol-6-yl ]benzamide; multi-target protein kinase, especially epidermal and endothrlial growth factor, inhibitors; antiproliferative, anticarcinogenic agent | 4SC AG (DE) | 2009-08-18 | — | — | US | disclosed |
| US-7576090-B2 | e.g. N-[2-(6,7-Dimethoxyquinazolin-4-ylamino)benzothiazol-6-yl ]benzamide; multi-target protein kinase, especially epidermal and endothrlial growth factor, inhibitors; antiproliferative, anticarcinogenic agent | 4SC AG (DE) | 2009-08-18 | — | — | US | disclosed |
| US-7576090-B2 | e.g. N-[2-(6,7-Dimethoxyquinazolin-4-ylamino)benzothiazol-6-yl ]benzamide; multi-target protein kinase, especially epidermal and endothrlial growth factor, inhibitors; antiproliferative, anticarcinogenic agent | 4SC AG (DE) | 2009-08-18 | — | — | US | disclosed |
| EP-1833823-A1 | 2,5- AND 2,6-DISUBSTITUTED BENZAZOLE ANALOGUES USEFUL AS PROTEIN KINASE INHIBITORS | 4SC AG (DE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006069740-A1 | 2, 5 AND 2, 6-DISUBSTITUTED BENZAZOLE ANALOGUES USEFUL AS PROTEIN KINASE INHIBITORS | 4SC AG (DE) | 2006-07-06 | — | — | WO | disclosed |
| US-20060142570-A1 | Benzazole analogues and uses thereof | 4SC AG (DE) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142570-A1 | Benzazole analogues and uses thereof | CYP3A5, CYP3A7, CYP3A43 | EGFR 4233/4885KDR 4179/4885AURKA 1705/4885 |
| US-20110172241-A1 | Benzazole analogues and uses thereof | CYP3A5, CYP3A7, CYP3A43 | EGFR 4233/4885KDR 4179/4885AURKA 1705/4885 |
| US-20090270410-A1 | BENZAZOLE ANALOGUES AND USES THEREOF | CYP3A5, CYP3A7, CYP3A43 | EGFR 4205/4885KDR 4089/4885AURKA 1801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.